FDA approves Rasonque pill for metastatic pancreatic cancer
The U.S. Food and Drug Administration authorized Rasonque, an oral inhibitor that targets multiple forms of the RAS protein, for adults with metastatic pancreatic cancer who either failed at least one prior treatment or cannot receive certain combination therapies. The approval followed a randomized, open-label trial of 500 pretreated patients in which Rasonque produced a median overall survival of 13.2 months versus 6.7 months with standard chemotherapy. Regulators accelerated the decision through priority review, orphan drug and breakthrough therapy designations and used the FDA commissioner's National Priority Voucher pilot program; an expanded access protocol was opened earlier. Common adverse events included rash, diarrhea, stomatitis and hemorrhage.
Rasonque doubled median survival in a 500-patient trial.
Context
The FDA reviewed trial data showing a large survival benefit. The agency used expedited programs and opened expanded access, and it may watch safety and later studies.
The full analysis
19 dimensions on this story — world impact, market read, and what happens next.
- Full ContextLocked
- Affected SectorsLocked
- Stock ImpactLocked
- Investor RelevanceLocked
- Professional RelevanceLocked
- Watch PointsLocked
- Probability of ChangeLocked
- Debate PointsLocked
- Prerequisite KnowledgeLocked
- Follow-up QuestionsLocked
- Pros & ConsLocked